News Center

Home page

Peak Report

News reports

Announcement on Participating in the Major Asset Reorganization of Tianshan Stock

Release time:

2021-05-20

Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Lin 2020-016

Zhejiang Jianfeng Group Co., Ltd.

Announcement

on Participating in Major Asset Reorganization of Tianshan Stock Company The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents

Important Content Note:

0.95336% of its registered capital). The company intends to participate in the major asset reorganization being planned by Xinjiang Tianshan Cement Co., Ltd. (hereinafter referred to as "Tianshan shares"), and convert all the shares of Southern Cement held by the company into shares issued by Tianshan shares. If the transaction is successfully implemented, the Company will no longer hold an equity interest in Southern Cement and will instead hold an equity interest in Tianshan shares.
1. Transaction Basic Information
(I) Transaction Overview
The Company currently holds 105 million yuan equity of Southern Cement, accounting for 0.95336% of its registered capital (hereinafter referred to as the target equity).
2020 On July 25, Tianshan shares disclosed the "Announcement on the Suspension of Trading on Planning for Major Asset Restructuring Matters", Tianshan shares and China Building Materials Co., Ltd. (hereinafter referred to as "China Building Materials") are planning major asset restructuring Related matters, Tianshan shares plans to issue shares to acquire the assets of China Building Materials Cement Plate (hereinafter referred to as "this transaction"), the underlying assets of the transaction include Southern Cement, a participating subsidiary of the Company.
In order to further optimize the company's asset structure, the company intends to participate in the planned major asset reorganization of Tianshan shares and the exchange of shares of Southern Cement and Tianshan shares.
(II) Board of Directors Deliberation
2020 On August 7, the company held the 15th meeting of the 10th board of directors by means of communication voting. All eight directors of the company participated in the meeting. After deliberation and voting, the board of directors deliberated and passed the matter with 8 votes in favor, 0 votes against and 0 abstentions.

(III) According to the Shanghai Stock Exchange's "Stock Listing Rules" and "Articles of Association" and other relevant regulations, the company's participation in the major asset reorganization of Tianshan shares is within the scope of the board of directors. The transaction is not a related party transaction of the company, nor does it constitute a major asset reorganization of the company as stipulated in the administrative measures for major asset reorganization of listed companies.

Basic Information of 2. Trading Parties

Basic Information of (I)

Tianshan Stock

, Enterprise Name: Xinjiang Tianshan Cement Co., Ltd.

, Enterprise Type: Other Joint Stock Co., Ltd. (Listed)

, Registered Address: baiyanggou Village, Dabancheng District, Urumqi City, Xinjiang

, Office Address: Tianhe Building 5 , No.

1256

, Hebei East Road, Urumqi City, Registration Date: 1998 11 18

, Legal Representative: Zhao Xinjun

, Registered Capital: 104,872.2959 yuan

, scope of business: development, production, sales and technical services of cement and related products; Import and export business of building materials products; Production and sales of commercial concrete; Mining, processing and sales of limestone and sandstone; Rental of houses and equipment; Financial consultation; Technical consultation; Cargo transportation agency; Loading, unloading and handling services; freight information, business information consultation; steel, rubber and plastic products, metal materials, metal products, water-based coatings, wires and cables, mechanical equipment, mechanical and electrical equipment, wood, stone, refractory materials, glass ceramic products, environmental protection equipment, hardware and electrical appliances, instruments Sales of meters, electronic products, digital products, electronic components, communication equipment; commodity purchasing agents; sales of industrial waste slag used in the production of limestone, cement and concrete; mining, processing and sales of gypsum; production and sales of cement products, cement clinker, pulverized coal slag and concrete aggregate; manufacturing, installation and maintenance of cement and commercial mixing equipment; import and export of general goods and technology. (Projects subject to approval according to law can only be operated with the approval of relevant departments)

, Tianshan Stock's actual controllers: China Building Materials Group Co., Ltd.

, Main Financial Indicators

Tianshan Stock's 2019 Annual Report and 2020 First Quarter Report Disclosure: audited by Tianzhi International Certified Public Accountants (Special General Partnership) (Tian Career Zi [2020] No. 5306), as of December 31, 2019, the total assets of the consolidated statement of Tianshan shares were 15.278 billion yuan, and the total owner's equity was 10.138 billion yuan. The owner's equity attributable to the parent company is 9.647 billion yuan; the operating income in 2019 is 9.688 billion yuan, the net profit is 1.829 billion yuan, and the net profit attributable to the owner of the parent company is 1.636 billion yuan.

As of 2020

, March , November, May , 31 , Tianshan Stock Co., Ltd. had consolidated assets of 154.43 .9 billion yuan, total owner's equity of 101.27 .1 billion yuan, and owner's equity of 96.17 of .3 billion yuan. 2020 1-3 July Consolidated operating income 5.35 .9 billion yuan, net profit -0.12 .1 billion yuan, net profit attributable to parent -0.30 .3 billion yuan. The above data is not audited. Basic Information of (II) Southern Cement

, Enterprise Name: Southern Cement Co., Ltd.

, Enterprise Type: Other Limited Liability Company

, Registered Address: shanghai Pudong century avenue

1600 20 Building 07-13 Room 4

, Office Address: Shanghai Pudong New Area Expo Museum Road

China Building Materials Building 8 Building 5

, Registration Date:

2007 09 April 05 6

, legal representative: Cao Jianglin

, registered capital:

1,101,363.3368 .74 million Yuan 8

, business scope: production of cement clinker, cement and its products, commercial concrete and its products, limestone (limited to subsidiaries and branches), research and development, sales, coal management, gypsum, electrical accessories, industrial equipment, chemical products (except dangerous chemicals, Monitoring chemicals, fireworks, civil explosives, precursor chemicals), refractory materials, cement packaging bags, labor protection products sales, investment in cement enterprises, software information technology services, project management services. (Projects subject to approval according to law can only be operated with the approval of relevant departments)

, the actual controller of Southern Cement: China Building Materials Group Co., Ltd.

Main Financial Indicators Southern Cement's 2019 Annual Report and 2020 First Quarter Report Disclosure: audited by Tianzhi International Certified Public Accountants (Special General Partnership) (Tian Career Zi [2020] No. 17648), as of December 31, 2019, the total assets of Southern Cement's consolidated statement were 85.812 billion yuan, and the total owner's equity was 29.528 billion yuan. The owner's equity attributable to the parent company is 27.299 billion yuan; the total operating income in 2019 is 66.968 billion yuan, the net profit is 5.951 billion yuan, and the net profit attributable to the owner of the parent company is 5.488 billion yuan.

As of March 31, 2020, the total assets in the consolidated statement of Southern Cement are 90.085 billion yuan, the total owner's equity is 30.978 billion yuan, and the owner's equity attributable to the parent company is 28.455 billion yuan; from January to March 2020, the total operating income is 9.17 billion yuan, the net profit is 1.451 billion yuan, and the net profit attributable to the owner of the parent company is 1.156 billion yuan. The above data is not audited. The main contents of the

3. transaction

Tianshan shares and China building materials are planning major asset restructuring related matters. Tianshan shares plans to issue shares to acquire the assets of China building materials cement plate. the target assets include all or part of the shares of China United cement group co., ltd., southern cement co., ltd., southwest cement co., ltd. and Sinoma cement co. 2

, the company plans to participate in the major asset reorganization of

Tianshan shares , and convert the shares issued by Tianshan shares with all 105 million yuan Nanfang Cement shares (accounting for 0.95336 of its registered capital ) . If the transaction is successfully implemented, the Company will no longer hold an equity interest in Southern Cement and will instead hold an equity interest in Tianshan. 3

, the valuation base date of the transaction is June 30, 2020, and the consideration for the transfer of the subject equity will be

determined based on the valuation results issued by the asset valuation agency and filed with the state-owned right unit . 4

and

The pricing benchmark date for the issuance of Tianshan shares in this transaction is the announcement date of the first board of directors resolution for Tianshan shares to consider the purchase of assets by this issue. The issue price is determined to be 13.38 yuan / shares according to the principle of not less than 90% of the average trading price of Tianshan shares in the 218 219 trading days before the pricing benchmark date. At the same time, in order to cope with the possible impact of the stock price fluctuations of listed companies caused by market and industry factors on the purchase of assets, the corresponding price adjustment mechanism has been formulated. 5 . The number of shares of Tianshan shares acquired by the Company in this transaction has not yet been determined, and will be calculated based on the final determination of the underlying equity transfer consideration and the issue price of Tianshan shares.

4. the impact of this transaction on the company

this time the company participates in the major asset restructuring of Tianshan shares with its equity in southern cement. if the

transaction can be successfully implemented

, it will be conducive to further optimizing the asset structure of the company. The company will acquire the newly issued shares of Tianshan shares and become a shareholder of Tianshan shares, which shall not be transferred within 12

months after the 237 of the issue. After the completion of the share issue, the company's participation in the major asset restructuring of Tianshan shares to enjoy the shares of Tianshan shares, such as bonus shares, transfer of share capital and other shares, also abide by the above-mentioned sales restriction period. If the company's commitment to the restricted period of the shares acquired based on its participation in the major asset restructuring of Tianshan shares is inconsistent with the latest regulatory opinions of the securities regulatory authorities, the company will make corresponding adjustments in accordance with the regulatory opinions of the relevant securities regulatory authorities.

5. Risk Tips

The major asset restructuring of Tianshan shares is still in the planning stage, the specific plan is still being demonstrated and improved, and the parties to the transaction still need to perform the necessary procedures and obtain the approval of the competent regulatory authority before it can be formally implemented, and there is still uncertainty as to whether it can be implemented. Please the majority of investors to pay attention to investment risk.

hereby announce

Zhejiang Jianfeng Group Co., Ltd.

Board of Directors

August 7, 2020

More information

Yunnan peak through the safety standard secondary acceptance

On March 21, Yunnan Jianfeng Cement Company successfully passed the evaluation and acceptance of secondary enterprises for safety production standardization. On the same day, a review team composed of leaders of the Yunnan Provincial Work Safety Supervision Bureau and relevant experts reviewed the implementation of the establishment of Yunnan Jianfeng safety production standardization secondary enterprises. According to the 13 elements involved in the "Standard for Assessment and Rating of Safety Production Standardization in Cement Enterprises", the review team conducted strict assessment and scoring item by item through grouping to check the site and review the data, and finally determined that Yunnan Peak passed the standard acceptance of safety standardization secondary enterprises. Yunnan Jianfeng has always attached great importance to safety production. After passing the three-level safety standard enterprise review in 2015, in order to raise the level of enterprise safety management to a new level, in 2016, it began to create secondary safety standardization. Over the past year, Yunnan Jianfeng has insisted on taking the creation of secondary safety standards as the top priority of production and operation management, and has formulated an implementation plan for production safety standardization in accordance with the requirements of national standardization norms. the content covers production safety responsibility system, education and training, safety inspection, safety facilities management and other safety production management standards, systems and post safety operation procedures, while further strengthening daily safety inspection and regularly organizing emergency plan drills, strengthen the investigation and rectification of potential safety hazards and the supervision of important hazard sources, and further consolidate the foundation of enterprise safety production management. After the review, Zhou Jiping, general manager of Yunnan Jianfeng, said that Yunnan Jianfeng will take this standard as a new starting point. On the basis of consolidating the accident-free achievements in production safety for two consecutive years, it will conscientiously implement the main responsibility of production safety and cultivate

2020

07-30

Pharmaceutical Company Invests in Beihui Bio-Peak Pharmaceutical Plate to Expand its Territory

News from our newspaper On February 28, the 10th meeting of the 9th Board of Directors of the Group Company reviewed and approved the "Proposal on Foreign Investment of Subsidiaries" and the "Proposal on Authorizing the Chairman of the Board of Directors." On the same day, Jianfeng Pharmaceutical signed the "Agreement on Capital Increase and Share Transfer of Beijing Huibaoyuan Biotechnology Co., Ltd." and the "Performance Commitment Compensation Agreement" with relevant parties. It is planned to use Beijing Huibaoyuan Biotechnology Co., Ltd. (Beihui Biotechnology) and its holding subsidiary Guangxi Huibaoyuan Pharmaceutical Technology Co., Ltd. (Guanghui Pharmaceutical) as a platform to jointly carry out new drug research and development, drug production and operation and other pharmaceutical business cooperation. Beihui Biological formerly known as Beijing Huibaoyuan Biotechnology Co., Ltd. The company has strong capabilities in new drug research and development. The actual controller is James Zhou (Zhou Hua), a returned entrepreneurial Ph.D. from Yale University in the United States, and hired Professor Zheng Yongqi from Yale University in the United States as the director of the Huibaoyuan Science and Technology Committee, focusing on anti-tumor and liver disease research. Through the cooperation with Yale University, we have obtained the patent authorization and commercial development license of the new anti-cancer chemical drug trasatabine (trokacitabine)(which has obtained the national new drug clinical approval in August 2016), the anti-hepatitis B chemical drug Crevudine (Clevudine). Guangxi Huibaoyuan Pharmaceutical Technology Co., Ltd., a subsidiary of Beihui Biology, is located in the third international park "China-Malaysia Qinzhou Industrial Park" jointly built by the Chinese government and foreign governments in Guangxi. It covers an area of 214.46 mu and has production workshops for multiple dosage forms such as percolation, tincture, solid preparations and liquid preparations.

2020

07-31

Peak health marketing and a new "play"

Building a New System, Flattening Management, Spike Health Marketing, New "Fit" On February 17, Spike Health Technology Company held a sales meeting to integrate and adjust the construction of a new marketing system and deploy and implement the 2017 sales work. Chen Daiyou, general manager of Health Technology Company, carefully explained and answered the marketing system construction and sales management assessment methods at the meeting, and reached a consensus on unifying thinking. The sales business of Health Technology Company involves three categories: health care products, plant extracts and Chinese herbal pieces. The product attributes and categories are different, and the product sales channels are diversified. In order to facilitate market expansion and adapt to the rapid response to market changes, the Company focuses on key products, key channels and key markets, adjusts the original division model, combines all sales businesses of the Company, establishes a marketing center, and centralizes and unifies flat management. At the meeting, the Health Technology Company issued the "2017 Sales Management Assessment Measures", which takes sales performance as the leading factor, defines the sales staff's business expenses and market expansion support policies, implements quarterly and annual assessment of sales targets, and directly links the assessment of the progress of sales staff's target tasks with monthly income. After two-way selection, adjustment and implementation of sales positions and target tasks, all sales staff of Health Technology Company have signed a sales economic responsibility system. Chen Daiyou hopes that marketers will build confidence to meet the challenges and grow and progress together with the enterprise. At the same time, he said that the health technology company will focus on strengthening the construction and cultivation of the sales team, and carry out training, learning and experience sharing in various ways, so as to improve the business ability and level of the sales team. (Spike Health)

2020

07-31

Peak health marketing and a new "play"

Building a New System, Flattening Management, Spike Health Marketing, New "Way to Work" On February 17, Spike Health Technology Company held a sales meeting to integrate and adjust the construction of a new marketing system and deploy and implement the 2017 sales work. Chen Daiyou, general manager of Health Technology Company, carefully explained and answered the marketing system construction and sales management assessment methods at the meeting, and reached a consensus on unifying thinking. The sales business of Health Technology Company involves three categories: health care products, plant extracts and Chinese herbal pieces. The product attributes and categories are different, and the product sales channels are diversified. In order to facilitate market expansion and adapt to the rapid response to market changes, the Company focuses on key products, key channels and key markets, adjusts the original business model, unifies all sales businesses of the Company, establishes a marketing center, and centralizes and unifies flat management. At the meeting, the Health Technology Company issued the "2017 Sales Management Assessment Measures", which takes sales performance as the leading factor, defines the sales staff's business expenses and market expansion support policies, implements quarterly and annual assessment of sales targets, and directly links the assessment of the progress of sales staff's target tasks with monthly income. After two-way selection, adjustment and implementation of sales positions and target tasks, all sales staff of Health Technology Company have signed a sales economic responsibility system. Chen Daiyou hopes that marketers will build confidence to meet the challenges and grow and progress together with the enterprise. At the same time, he said that the health technology company will focus on strengthening the construction and cultivation of the sales team, and carry out training, learning and experience sharing in various ways, so as to improve the business ability and level of the sales team. (Spike Health)

2020

07-31

Accident-free factory creation enters "second season"

At the beginning of the new year, a major "highlight" of the company's safety and environmental protection management in recent years-the "second quarter" of the establishment of a safety and environmental protection accident-free factory has also begun. Safety and environmental protection accident-free factory creation activities are an important measure for the company to improve the level of on-site management. The first phase of the activity will start on January 1, 2014 and end at the end of 2016 for a period of three years. Since the launch of the activity, all subordinate enterprises of the company have actively organized publicity and training related to safety and environmental protection, strengthened the awareness of safety and environmental protection of all employees, improved the management and operation level of safety and environmental protection; increased investment in safety and environmental protection facilities and equipment; strengthened safety and environmental protection inspection and self-examination and correction of hidden dangers, and timely organized rectification of hidden dangers; strictly assessed the units and relevant responsible persons of the accident, And the accident situation in the group, in order to arouse vigilance and avoid similar accidents. In the past three years, the company's subsidiaries have achieved remarkable results in standardization, safety, and clean operation. Safety and environmental protection accidents have dropped significantly, and no major accidents have occurred, which has effectively promoted the company's safe and civilized production construction. In the 2016 safety and environmental protection accident-free factory establishment assessment conducted a few days ago, a total of 6 units met the accident-free factory standard, of which Yunnan Jianfeng, Jianfeng International Trade and Pharmaceutical Department met the standard for the second consecutive year, and Daye Jianfeng, Qiubin Factory and Cable Company met the standard in the first year. In order to sum up experience and further improve the level of safety and environmental protection management, the Group decided to continue to open

2020

07-31

What will the Chinese Medicine Act bring us?

At the 25th meeting of the Standing Committee of the 12th National People's Congress in December 2016, the the People's Republic of China Chinese Medicine Law (hereinafter referred to as the Chinese Medicine Law) was deliberated and passed, which will come into effect on July 1 this year. As the first comprehensive law that comprehensively and systematically embodies the characteristics of traditional Chinese medicine, the Law of traditional Chinese Medicine clearly stipulates the service of traditional Chinese medicine, the protection and development of traditional Chinese medicine, the training of talents of traditional Chinese medicine, and the scientific research of traditional Chinese medicine. With the change of people's health concept and the continuous innovation of medical mode in recent years, the role of traditional Chinese medicine in health is becoming more and more important. The promulgation of the "Traditional Chinese Medicine Law" has made the development of Chinese medicine more law-based, and it is bound to bring changes to domestic pharmaceutical companies. So, the peak of the pharmaceutical, health products companies will look at the "Chinese Medicine Law", and will have how to deal with it? A few days ago, the reporter interviewed the pharmaceutical companies and peak health technology companies related to the person in charge. What will the Chinese Medicine Act bring us? Reporter: As the general manager of Peak Pharmaceutical, what do you think of the Chinese Medicine Law? Huang Jinlong (Deputy General Manager of the Group Company and General Manager of the Pharmaceutical Company): the Law of traditional Chinese Medicine defines the important position and development policy of traditional Chinese medicine. The state encourages traditional Chinese medicine and western medicine to learn from each other, complement each other, coordinate development, give full play to their respective advantages, and promote the integration of traditional Chinese and western medicine. Traditional Chinese medicine is a huge knowledge system, reflecting the Chinese nation's understanding of life, health and disease. It is precisely because of the distinctive characteristics of Chinese medicine that the Law of Chinese Medicine is used in Chinese medicine clinics, Chinese medicine physicians and doctors.

2020

07-31

< 1...49 50 51...61 > 跳转到页